These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 23270927)
21. Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. Russell MR; Levin K; Rader J; Belcastro L; Li Y; Martinez D; Pawel B; Shumway SD; Maris JM; Cole KA Cancer Res; 2013 Jan; 73(2):776-84. PubMed ID: 23135916 [TBL] [Abstract][Full Text] [Related]
22. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911 [TBL] [Abstract][Full Text] [Related]
23. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Kreahling JM; Gemmer JY; Reed D; Letson D; Bui M; Altiok S Mol Cancer Ther; 2012 Jan; 11(1):174-82. PubMed ID: 22084170 [TBL] [Abstract][Full Text] [Related]
24. Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma. Indovina P; Marcelli E; Di Marzo D; Casini N; Forte IM; Giorgi F; Alfano L; Pentimalli F; Giordano A Cancer Biol Ther; 2014 Apr; 15(4):380-8. PubMed ID: 24365782 [TBL] [Abstract][Full Text] [Related]
25. Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma. Lescarbeau RS; Lei L; Bakken KK; Sims PA; Sarkaria JN; Canoll P; White FM Mol Cancer Ther; 2016 Jun; 15(6):1332-43. PubMed ID: 27196784 [TBL] [Abstract][Full Text] [Related]
26. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress. Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088 [TBL] [Abstract][Full Text] [Related]
27. MELK Inhibition in Diffuse Intrinsic Pontine Glioma. Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363 [No Abstract] [Full Text] [Related]
28. Targeting the checkpoint kinase WEE1: selective sensitization of cancer cells to DNA-damaging drugs. Indovina P; Giordano A Cancer Biol Ther; 2010 Apr; 9(7):523-5. PubMed ID: 20150761 [No Abstract] [Full Text] [Related]
29. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair. Kausar T; Schreiber JS; Karnak D; Parsels LA; Parsels JD; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA Neoplasia; 2015 Oct; 17(10):757-66. PubMed ID: 26585231 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma. Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603 [TBL] [Abstract][Full Text] [Related]
31. ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors. de Gooijer MC; Buil LCM; Beijnen JH; van Tellingen O Invest New Drugs; 2018 Jun; 36(3):380-387. PubMed ID: 29147815 [TBL] [Abstract][Full Text] [Related]
32. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Van Linden AA; Baturin D; Ford JB; Fosmire SP; Gardner L; Korch C; Reigan P; Porter CC Mol Cancer Ther; 2013 Dec; 12(12):2675-84. PubMed ID: 24121103 [TBL] [Abstract][Full Text] [Related]
33. Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer. Geenen JJJ; Schellens JHM Clin Cancer Res; 2017 Aug; 23(16):4540-4544. PubMed ID: 28442503 [TBL] [Abstract][Full Text] [Related]